Guy's Hospital Offers Wegovy Weight Loss Treatment

Guy's Hospital in London is among the first NHS facilities to prescribe Wegovy, a weight-loss drug intended for patients with a BMI over 35, potentially benefiting 3.4 million UK adults. Concurrently, Novo Nordisk has reported that a higher 7.2 mg dose of Wegovy results in significant weight loss, with patients losing up to 20.7% of their body weight over 72 weeks, compared to 17.5% with the standard 2.4 mg dose. Despite these promising results, Eli Lilly's competitor drug Zepbound has shown slightly greater efficacy, with patients achieving a 20.9% weight reduction. These findings suggest that while Wegovy's higher dosage enhances weight loss, it may still face stiff competition from Zepbound in the obesity treatment market. Novo Nordisk's data indicates that the higher dose could see broader adoption if safety and tolerability are maintained. The hospital's use of Wegovy reflects a growing trend in medically managed weight loss, emphasizing the importance of personalized treatment approaches.